Novel radiation therapy promising for metastatic castration-resistant prostate cancer
from Reuters Health News via MDLinx
A novel, targeted radiation therapy called Lutetium-177 PSMA-617 has shown promising clinical activity in men with prostate-specific membrane antigen-positive metastatic, castration-resistant prostate cancer that progressed despite multiple standard therapies. "LuPSMA provides a new approach to a form of the disease that has been difficult to treat," said the lead study investigator in a news release.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063